Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/70503—Immunoglobulin superfamily
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

• the invention relates to particular novel polypeptides capable of transducing a signal from an activator receptor for MHC class I molecules, functioning as a stand-alone receptor or as a co-receptor, and from a KAR (Killer -cell Activatory Receptor) in particular, on the antibodies obtained from said polypeptides serving as immunogens, and on the nucleic acids corresponding to said polypeptides.
• KAR Killer -cell Activatory Receptor
• the invention also relates to the methods for obtaining such polypeptides and to the biological applications, more particularly, preventive, therapeutic and diagnostic, of said polypeptides, antibodies and nucleic acids.
• the immune system must use a coordinated system of intercellular communications.
• BCR B lymphocyte antigen
• TCR T lymphocyte antigen
• RFc Fc portion of the antibodies
• KARs Killer cell Activatory Receptors
• KLRs Killer cell Inhibitory Receptors
• KARs and KIRs are not limited to NK cells: they are also naturally expressed by T cells.
• KARs are highly homologous to KIRs (up to 96% homology between KARs and KIRs at the extracytoplasmic level). KARs and KIRs do not, however, perform the same functions:
• KIRs are involved in the negative control (inhibitor) of activation of NK and T cells, while KARs are involved in the positive control (stimulator) of activation of NK and T cells.
• KAR activating isoform
• KIR inhibiting isoform
• KARs express a charged amino acid residue (lysine) in their transmembrane domain and do not contain any ITLM motif (immunoreceptor inhibition motif based on tyrosine residue (s)) in their intracytoplasmic domain.
• ITLM motif immunoglobulin-like motif
• the KAR monomeric receptors do not contain an ITAM motif (immunoreceptor activation motif based on tyrosine residue (s)).
• NKG2C / D which is of the lectin type and whose inhibitory counterpart is NKG2A / B
• non-inhibitory receptors such as SIRP ⁇ and LLT 1, whose ligands are still unknown and which have been described either on hematopoietic cells and on non-hematopoietic cells (SIRP ⁇ ), ie on B cells, macrophages and dendritic cells (ILT1).
• KARs can function as autonomous receptors, in particular for MHC class I molecules. It is thus known that the engagement of KARs with MHC class I molecules expressed on the surface of target cells, initiates the programs of lymphocyte activation as established due to the mobilization of intracytoplasmic Ca 2+ and the induction of lysis of target cells.
• KARs can also provide co-receptor functions for TCR and RFc receptors (Mandelboim O. et ai, 1996, Science 274: 2097; Cambiaggi A. et al., 1996 , Blood 87: 2369).
• KARs can play the role of co-receptors and thus increase the intensity of the cellular response, in particular in the face of small quantities of antigens, maintain the cellular response over time, and also cooperate stimulation of cell proliferation.
• KARs naturally expressed in NK and T lymphocyte subpopulations, is not restricted by their own ligands, namely MHC class I molecules, but extends to the equilibrium of the immune system in a way general.
• the functioning of naturally expressed KARs thus influences the proliferation of NK and T cells, the production by such cells of cytokine-like substances, the lysis of target cells such as autologous cells which are deleterious, malignant or infected with viruses, cells allogenic, but also on the tolerance of the immune system to certain antigens.
• Any failure or dysfunction of the KARs can therefore lead to various pathologies or undesirable reactions, all linked to the functioning of the immune system, such as immunodeficiency diseases, autoimmune diseases (eg multiple sclerosis), tumors, infections viral, bacterial, parasitic, allergies, transplant rejections. It has, for example, been shown that if humans have on average less than 10% of lymphocytes expressing KARs, almost all of the lymphocytes of patients suffering from LDGL (lymphoproliferative disease of granular lymphocytes) express KARs.
• LDGL lymphoproliferative disease of granular lymphocytes
• the object of the present invention is to provide means making it possible to diagnose abnormal or unwanted functioning of activating receptors for MHC class I molecules such as KARs and to control their functioning.
• KARAP KAR-Associated Proteins
• KAR receptor we mean, in the present case, human receptors of the immunoglobulin type non-inhibitory counterparts of the KIR receptors, such as the KAR p50 receptors (KTRTLOS1 to TRILDS5), KTRIILDSl, but also any non-inhibitory receptor of structure similar to these KAR receptors, and in particular human receptors of the lectin type such as NKG2C, NKG2D (naturally expressed on NK and T cells), murine receptors of the immunoglobulin type such as pir A (naturally expressed on myeloid cells, B cells) , gp49A (naturally expressed on mast cells), murine lectin receptors such as Ly49D, Ly49H (naturally expressed on NK and T cells).
• KAR receptor we mean, in the present case, human receptors of the immunoglobulin type non-inhibitory counterparts of the KIR receptors, such as the KAR p50 receptors (KTRTLOS1 to TRILDS5), KTRIILDSl, but also any non
• KARAP polypeptide any isolated polypeptide (other than a KAR) in the absence of which said KAR receptor is naturally incapable of transducing a detectable activating signal. This does not exclude the fact that a determined KARAP polypeptide can not only associate with a KAR receptor as defined above, but also with other activating or non-inhibiting monomeric receptors with a structure close to that of KARs such as defined above, and in particular to a human activating receptor of the immunoglobulin type of the LIR / MIR / LLT family such as LLT1.
• polypeptide includes, in the present application, not only said polypeptide, but also the homologs of this polypeptide, as obtained by deletion, insertion, inversion or conservative substitution of amino acids, and the fragments of this polypeptide, as obtained by hydrolysis of said polypeptide using proteases, said homologs or fragments being capable of transducing a signal originating from a KAR.
• polypeptide covers, in the present application, both polypeptides and proteins.
• a polypeptide according to the invention is necessary for the transduction of the signal received by a KAR receptor: it is therefore an isolated polypeptide which allows the restoration of a deficient KAR activation.
• the skilled person can proceed by showing that there is a KAR receptor which, if expressed by an appropriate cell in the absence of this polypeptide , fails to transduce a detectable activator signal, or fails to transduce an activator signal satisfactory for the intended application.
• Example 3 One embodiment of this determination is presented in Example 3 below by comparison between the activation capacity (serotonin release) of an RBL-2H3 cell expressing the KAR p50.2 receptor alone, and that of an RBL-2H3 cell which expresses both the KAR p50.2 receptor and its KARAP polypeptide. Examples of suitable cells are shown in Figure 5 below.
• restored deficient KAR activation we mean that transduction, at the cell, by said KAR of a significant activating signal is possible, or, if necessary, satisfactory. This can be tested in particular using cellular stimulation with antibodies. To determine at the cell level whether a signal from a
• KAR is or is not transduced, and to determine whether such a signal is stimulated or inhibited
• numerous means are available to those skilled in the art. Examples of such means include stimulation of said KAR by a ligand and measurement of secreted cytokines (cf. for example, Cambiaggi et al. 1996, Blood 87: 2369), of cell proliferation (cf. for example Mandelboim et al. 1996, Science 274: 2097), cytotoxicity (cf. for example the redirected cytotoxicity test described below), mobilization of intracytoplasmic calcium (cf. for example Bléry et al, 1997, J. Biol. Chem. 272, 8989-8996), and / or the induction of phosphorylation (cf. for example Vivier et al. 1991, J. Immunol. 146: 206).
• cytokines cf. for example, Cambiaggi et al. 1996, Blood 87: 2369
• cell proliferation cf. for
• a polypeptide according to the invention is further characterized in that it is capable of associating with a KAR, and of not associating with the inhibitory counterpart of this KAR.
• Methods for determining whether a polypeptide is capable of associating with a KAR, and of not associating with the inhibitory counterpart of this KAR (i.e. of not associating with the corresponding KIR receptor ) are well known to those skilled in the art.
• An example of such a method includes in particular: - to express this polypeptide to a KAR + KIR " cell on the one hand, and to a KAR-KTR + cell,
• polypeptide fraction (s) from the lysate of these cells using at least anti-KAR and / or anti-KTR antibodies
• anti-KTR and / or anti-KAR antibodies include anti-CD158, anti-p70 / NKB1, anti-p140 antibodies, and more particularly monoclonal antibodies EB6, GL183 or PAX250.
• a method for expressing such a polypeptide by a cell is indicated in Example 3 below.
• a KARAP polypeptide according to the invention can moreover be characterized in that it is as obtained: i. by immunoprecipitation of one or more polypeptide fraction (s) of cell lysates expressing KAR receptors capable of transducing an activating signal using one or more anti-KTR and / or anti-KAR antibodies, such as (s) an anti-CD158, anti- ⁇ 70 / NKBl, anti-pl40 antibody, and more particularly the monoclonal antibody EB6, GL183 or PAX250, ii.
• each polypeptide fraction can optionally be further depleted by elimination of the immunoprecipitated fractions using anti-CD3 ⁇ and / or anti-Fc ⁇ RI ⁇ antibodies, and / or be precipitated again using one or more anti- KTR and / or anti-KAR such as an anti-CD158, anti-p70 / NKBl, anti-pl40 antibody, and more particularly the monoclonal antibody EB6, GL183 or PAX250, iii.
• Said cells expressing KAR receptors capable of transducing an activating signal can in particular be NK cells and / or T cells and / or myeloid cells and / or B cells and / or mast cells.
• Means for determining whether or not a KAR is capable of transducing a signal to the cell have been indicated above.
• - has a molecular mass of between 10 + 2 and 16 + 2 kDa approximately (in particular, actual molecular mass of 10 + 2 kDa, apparent molecular mass on polyacrylamide gel under denaturing conditions from l2 + 2 to l6 + 2kDa depending on the degree of phosphorylation).
• amino acid sequence comprises at least one ITAM motif YxxL / Ix ⁇ 5 .8YxxL / I in the intracytoplasmic region.
• the amino acid sequence of a KARAP polypeptide comprises an extracytoplasmic region, a transmembrane region, and / or an entracytoplasmic region.
• this intracytoplasmic region is predominant relative to the other regions of the sequence of this polypeptide.
• Means to identify extracytoplasmic, transmembrane regions, intracytoplasmic agents are known to those skilled in the art (for example, hydropathicity algorithms, formation of reverse vesicles).
• the amino acid sequence of a KARAP polypeptide comprises at least one extracytoplasmic cysteine amino acid.
• the amino acid sequence of a KARAP polypeptide comprises at least one charged amino acid (R, K, D, E) transmembrane.
• polypeptides according to the invention can be phosphorylated at the level of at least one tyrosine residue, or be non-phosphorylated.
• said polypeptides are in the form of dimers linked by a disulfide bridge; they associate in a selective and non-covalent manner with KARs which function, either as autonomous receptors for MHC class I molecules, or as co-receptors of TCR or of an RFc such as CD16.
• a KARAP polypeptide is capable of binding to a molecule with an SH2 domain such as ZAP-70, p72 ⁇ , p56, p59 ⁇ , p60 / w , Grb-2, pp36-38 (lat ), PLC- ⁇ l, p85 (PI-3 kinase), Shc, or to a molecule with a PTB domain (PhosphoTyrosine Binding) such as Shc.
• SH2 domain such as ZAP-70, p72 ⁇ , p56, p59 ⁇ , p60 / w , Grb-2, pp36-38 (lat ), PLC- ⁇ l, p85 (PI-3 kinase), Shc
• PTB domain PhosphoTyrosine Binding
• a particular KARAP polypeptide according to the invention has an amino acid sequence essentially constituted by SEQ ID No. 2.
• the present invention also relates to the polypeptides whose sequence is essentially constituted by the extracytoplasmic part of SEQ LD n ° 2, namely SEQ ID n ° 3, or by the transmembrane part of SEQ LD n ° 2, namely SEQ ID No. 4, or the intracytoplasmic part of SEQ LD No. 2, namely SEQ ID No. 5.
• Other specific KARAP polypeptides according to the invention have an amino acid sequence essentially constituted by SEQ ID No. 11, No. 12, No. 13, No. 14, No. 15, No. 17 (consensus sequence of the mouse KARAP protein C57B1 / 6), or No. 28 (mouse KARAP protein sequence 129 obtained from the genomic sequence).
• polypeptides can also be obtained, after sequencing, by climatic synthesis or using recombinant DNA techniques.
• Said KARAPs polypeptides are necessary for the transduction of signals originating from activating receptors, the KARs, which do not present ITEVI or ITAM intracytoplasmic but which have a transmembrane amino acid residue.
• the polypeptides according to the invention are modified by glycosylation, phosphorylation, sulfonation, biotinylation, acylation, esterification, or by addition, substitution, deletion of entities of molecular form close to that of phosphate groups, such as phosphonate , by addition of labeling reagents such as luciferase, GFP (Green Fluorescence Protein) or its analogs, by addition of purification targets such as an affinity ligand, by addition of entities modifying its solubility.
• Modifications of particular interest include those which modify said polypeptide so as to block or inhibit its ability to transduce the signal received (strategy of the transdominant negative).
• a polypeptide according to the invention in a form thus modified, finds in particular applications in any composition or method intended to negatively modulate (inhibit) a given immune response, in particular an unwanted or abnormal immune response (for example, auto-diseases - immune, allergies, transplant rejection).
• Appropriate modifications include those which render the tyrosine phosphorylation of said polypeptide non-hydrolyzable under biological conditions (for example, by addition of phosphonate groups).
• tyrosine residues Y
• ITAM motif a tyrosine residue contained in an ITAM motif
• F a phenylalanine residue
• polypeptides of the invention are capable of crossing a cell membrane, that is to say a lipid bilayer.
• the present invention also relates to the antibodies, in particular the monoclonal antibodies, and the fragments of such antibodies, in particular the Fc, Fv, Fab, F (ab) ′ 2 , CDR fragments, as obtained by immunogenesis from a KARAP polypeptide according to the invention, or as obtained from a fragment, homologous or modified form of such a polypeptide.
• fragments of such antibodies in particular fragment Fc, Fv, Fab, F (ab) '2, CDR, as obtained by immunogenesis from a polypeptide whose sequence consists essentially of the extracytoplasmic, intracytoplasmic or transmembrane part of such a KARAP polypeptide according to the invention.
• Such antibodies are obtained by immunization of animals, such as rabbits and mice, against polypeptides, fragments, homologs or modified forms according to the invention as essentially obtained by elution of electrophoretic bands, by chemical synthesis or by a technique of soluble fusion proteins (GST), said polypeptides, fragments, homologs or modified forms being optionally coupled to immunogens such as ovalbumin.
• animals such as rabbits and mice
• polypeptides, fragments, homologs or modified forms as essentially obtained by elution of electrophoretic bands, by chemical synthesis or by a technique of soluble fusion proteins (GST), said polypeptides, fragments, homologs or modified forms being optionally coupled to immunogens such as ovalbumin.
• immunogens such as ovalbumin.
• Monoclonal antibodies are then produced by hybridoma fusion of immune spleen cells, screening and purification of culture supernatants (Kôhler and Milstein, 1975, Nature 256, 495-497; Antibodies, a laboratory manual, 1988, Harlow and David Lane, Ed. Cold Spring Harbor laboratory).
• diantibodies can be generated according to standard procedures. Said fragments can, if necessary, be inserted or grafted to humanizing structures.
• the present invention also relates to nucleic acids comprising a sequence corresponding to reading in an open frame, according to the universal genetic code and taking into account the degeneration of said code, of the amino acid sequence of a polypeptide, fragment, or homologous according to the invention, as well as the variants which have a homology greater than or equal to 60% with such nucleic acids, and which are capable of coding for a transducer molecule of an activating signal originating from a KAR as defined above .
• nucleic acid whose DNA sequence is essentially constituted by SEQ LD n ° 1 (cDNA of the mature KARAP protein of sequence SEQ LD n ° 2), n ° 6, n ° 7, n ° 8, n ° 9, n ° 10, n ° 16 (consensus cDNA sequence of mouse KARAP C57B1 / 6), n ° 27 (cDNA sequence of mouse KARAP 129 obtained from the genomic sequence), n ° 18 (genomic sequence of KARAP mouse 129), or No.
• the present invention also relates to a process for obtaining a polypeptide according to the invention comprising the steps: i.
• NK cells and / or T cells and / or myeloid cells and / or B cells and / or mast cells for example immunoprecipitate one or more polypeptide fraction (s) of cell lysates expressing functional KAR receptors (NK cells and / or T cells and / or myeloid cells and / or B cells and / or mast cells for example ) using one or more anti-KIR and / or anti-KAR antibodies, such as an anti-CD158 antibody, anti-p70 NKBl, anti-pl40, and more particularly the monoclonal antibody EB6 ,
• each polypeptide fraction can optionally be further depleted by elimination of the immunoprecipitated fractions using anti-CD3 and / or anti-Fc ⁇ RI ⁇ antibodies, and / or can be precipitated again using one or more anti- KTR and / or anti-KAR such as an anti-CD158, anti-p70 / NKBl, anti-pl40 antibody, and more particularly the monoclonal antibody EB6, GL183 or PAX250, iii.
• the said polypeptide fraction (s) to a kinase test, and recovering the phosphorylated polypeptides corresponding to a molecular weight of approximately 12, 14 and / or 16 ⁇ 2 kDa.
• the present application also relates to a method for obtaining the sequence of specific KARAP polypeptides according to the invention. This method, an exemplary embodiment of which is described in Example 2 below
• bioinformatics strategies includes in particular the screening of those of the polypeptide sequences which meet the following criteria: the sequence has at least one phosphorylatable tyrosine amino acid,
• the sequence has a molecular mass of between approximately 5 and 25 kDa, the sequence comprises an extracytoplasmic region, a transmembrane region, and an intracytoplasmic region,
• the sequence comprises at least one amino acid cysteine in its extracytoplasmic region
• the sequence comprises at least one charged amino acid (R, K, D, E) in its transmembrane region, and
• the sequence comprises at least one ITAM motif YXXL / IX ⁇ - S YXXL / I in its intracytoplasmic region,
• the polypeptide corresponding to the selected sequence must be able to associate with a KAR, and not to associate with the corresponding inl ibitrix receptor receptor (KIR), as defined above.
• the present application also relates to a method for determining or checking whether a candidate polypeptide corresponds to a KARAP polypeptide according to the invention.
• An exemplary embodiment of such a method is presented in Example 2 below.
• One such method consists in producing an antibody against a characteristic part of this candidate polypeptide (for example an intracytoplasmic region comprising at least one ITAM motif or an extracytoplasmic region), and in verifying that there is a KAR receptor which, when it is expressed functionally on a cell, is associated with a recognized element, according to an antigen-antibody type reaction, by said antibody.
• This method for identifying KARAP polypeptides thus consists in particular in:
• the candidate polypeptide as being a KARAP polypeptide according to the invention when in the reaction products possibly formed there is a product of apparent molecular mass close to that of said activating or non-inhibiting receptor (approximately 50 kDa for KAR p50) and a product of apparent molecular mass close to that of the candidate polypeptide (in particular between 10 and 16 kDa approximately).
• This identification method according to the invention can in particular be carried out: by bringing said antibody into contact as described above,
• the present invention also relates to a pharmaceutical composition
• a pharmaceutical composition comprising, in association with a pharmaceutically acceptable vehicle, an effective amount of at least one polypeptide, KARAP, fragment, homologous or modified form according to the invention, of at least one antibody or fragment d antibody according to the invention, or at least one nucleic acid or variant nucleic acid according to the invention.
• composition according to the invention can be formulated in solid, liquid form or in the form of a suspension, for oral, parenteral, topical, intravaginal, mtrarectal administration or for oral and / or nasal inhalation.
• Said pharmaceutical composition according to the invention is intended to modulate the activity of a KAR.
• said pharmaceutical composition will comprise agents facilitating the transduction of the signal originating from said KAR, such as, for example, polypeptides, fragments, homologs, or nucleic acids, variants according to the invention capable of crossing a lipid bilayer.
• said pharmaceutical composition will comprise agents blocking the transduction of signals originating from said KAR such as, for example, antibody fragments according to the invention capable of crossing a lipid bilayer so as to block the Cellular KARAPs, or modified polypeptides, according to the invention, phosphorylated or not, for example phosphorylation not hydrolysable under biological conditions, so as to block proteins with domain SH2 (ZAP-70, p72 syk ) or PTB or any molecule adapter or effector of the activation of said KAR.
• modifications include in particular the addition of phosphonate groups, and / or the mutation of at least one Tyrosine residue (Y) to phenylalanine residue (F).
• the present application therefore relates to a composition for the prevention, palliation, and / or treatment of an abnormal or unwanted functioning of a cell involved in an immune reaction.
• a composition advantageously comprises polypeptides, or, where appropriate, modified polypeptides according to the invention.
• the present invention also relates to a method of in vitro diagnosis of abnormal or unwanted functioning of a cell comprising the steps of:
• the contacting step is carried out under conditions in particular of duration, temperature, buffer, if necessary of gel crosslinking, allowing the establishment of an antigen-antibody type reaction for example by ELISA (Enzyme Linked Immunoabsorbent Assays ), or, where appropriate, a reaction of the nucleic acid hybridization and PCR type (polymerase chain reaction).
• ELISA Enzyme Linked Immunoabsorbent Assays
• a reaction of the nucleic acid hybridization and PCR type polymerase chain reaction
• markers such as fluorescent, enzymatic, radioactive or luminescent markers can be used.
• Said in vitro diagnostic method according to the invention allows the diagnosis of abnormal or unwanted cellular functioning which can result in an immunoproliferative disease, an immunodeficiency disease such as a VLH disease, a cancer such as the lymphoproliferative disease of lymphocytes granular, an autoimmune disease such as rheumatoid arthritis, an infectious disease such as malaria, an allergic response, transplant rejection.
• the present invention also relates to a method of identifying molecules which are adapters or effectors of the activation of a KAR, and to a method of identifying molecules capable of modulating cellular activity resulting from the activation of a KAR. .
• the candidate molecules capable of being molecules that adapt or effect the activation of a KAR can for example be chosen from molecules with a SH2 or PTB domain. They can be in soluble recombinant form.
• the contacting step can be, for example, carried out by coupling the candidate molecules, obtained in soluble recombinant form, capable of being molecules that adapt or effect the activation of a KAR, to beads allowing the measurement.
• radioactivity such as scintillating liquid beads, and by passing over said beads, polypeptides according to the invention (or fragments or homologs of such polypeptides) under tritiated form. Are then selected those of the candidate molecules for which a binding to said polypeptides, fragments, or homologs is observed by measurement of radioactivity (cpm).
• the contacting step can also be carried out by immobilization of polypeptides according to the invention (or of fragments or homologs of such polypeptides) on microcarriers allowing the measurement of the resonance of plasmons such as BIAcore (Pharmacia) microcarriers (cf. for example Olcese et al., 1996, The Journal of Immunology 156: 4531-4534; Vélv et al, Immunology Letters 1996, vol. 54, pl45-150), or by immobilization of phosphorylated and biotinylated polypeptides according to the invention. streptavidin beads (Vély et al. Eur. J. Immunol. 1997, 27: 1994-2000; Le Dréan et al.
• This method of identifying molecules that are adapters or effectors of the activation of a KAR can also serve as a reference in the implementation of the method of identifying molecules capable of modulating cellular activity resulting from the activation of a KAR according to the invention.
• This method of identifying molecules capable of modulating cellular activity resulting from the activation of a KAR comprises the steps of: i. bringing candidate molecules into contact with molecules that are adapters or effectors of the activation of a KAR as obtained by method according to the invention described above and with polypeptides according to the invention (or with fragments or homologs of such polypeptides), and ii. selection of those of the candidate molecules which exert an effect on the link between said polypeptides (or said fragments or homologs of polypeptides) and said adapter or effector molecules, as observed in the absence of said candidate molecules.
• the candidate molecules capable of modulating cellular activity resulting from a KAR can be chosen from banks of natural or synthetic compounds, in particular from chemical or combinatorial banks.
• Said candidate molecules can be of a protein nature (for example, derivatives or fragments of anti-idiotype antibodies such as the antibodies according to the invention, derivatives or fragments of catalytic antibodies), of carbonaceous, lipid or nucleic nature.
• the step of bringing the method of identification of molecules capable of modulating cellular activity resulting from the activation of a KAR, according to the invention, into contact can, for example, be carried out by incubating said candidate molecules with polypeptides according to the invention (or with fragments or homologs of such polypeptides) and with molecules which adapt or effect the activation of a KAR, as obtained by the method according to the invention, under conditions allowing a measurement the rate of binding between said polypeptides and said adapter or effector molecules for the activation of a KAR, for example, based on a chemical property of said adapter or effector molecules in the unbound state, such as enzymatic property, property phosphorylation or self-phosphorylation.
• the step of bringing into contact the method of identifying molecules capable of modulating a cellular activity resulting from the activation of a KAR, according to the invention, can also be carried out by implementing techniques of the bead type. scintillating liquid and tritiated polypeptides or microsupport type and measurement of the plasmon resonance, as described above, by measuring the radioactivity or, respectively, the plasmon resonance, resulting from the bond between said polypeptides and said adapter or effector molecules, in the absence and in presence of candidate molecules. Those candidate molecules are then selected which either increase or decrease in a statistically significant manner the rate of control control measured between said polypeptides and said adapter or effector molecules in the absence of said candidate molecules.
• the molecules capable of modulating the activation of a KAR can be chemically modified so as to make them non-hydrolysable under biological conditions, and / or so that they can cross a cellular lipid bilayer.
• the molecules capable of modulating the activation of a KAR, according to the invention advantageously act by modifying the interaction between said KARAPs and their cellular effectors or adapters.
• Said molecules capable of modulating a cellular activity resulting from the activation of a KAR, according to the present invention can then be apphquée to a cell cultured in vitro, such as lymphocyte cell, whose KAR activity has been stimulated, for example , by contacting a ligand.
• a cell cultured in vitro such as lymphocyte cell, whose KAR activity has been stimulated, for example , by contacting a ligand.
• This application is made by penetration inside said cell, for example, by electroporation or by chemical modification allowing the crossing of a lipid bilayer.
• the present invention is illustrated by the following examples which are in no way to be considered as limiting. Reference is made to the following 23 figures: - Figure 1 shows in A, a flow cytometer analysis (FACScan, registered trademark
• LL-2 interleukin 2
• LDGL lymphoproliferative disease of granular lymphocytes
• B the results of a re-directed cytotoxicity test with different monoclonal antibodies, performed on NK cells cultured on LL-2 from different donors;
• FIG. 2 shows: in A, an SDS-PAGE analysis (resolution of proteins by gel electrophoresis and sodium dodecyl sulfate) carried out from NK cells of RP donor (p50.1 + ) radiolabeled at 125 I and immunoprecipitated at l using anti-CD158 EB6 monoclonal antibody, before and after depletion of Fc ⁇ RI ⁇ and CD3 ⁇ using anti-CD3 ⁇ / anti-Fc ⁇ RI ⁇ antibodies, in B, SDS-PAGE analysis with an anti- CD3 ⁇ of complete DF cell lysates or immunoprecipitates of such lysates;
• FIG. 3 shows: in A, an SDS-PAGE analysis of phosphorylated proteins from in vitro kinase tests to which immunoprecipitates of MAL NK cell lysates were subjected.
• B the same type of SDS-PAGE analysis as 'in Figure 3 A but performed from RBL-2H3 p50.2 + cells
• C an analysis by thin layer electrophoresis (TLE) of phosphorylated amino acids from the KARAPs and CD3 ⁇ bands excised after in vitro kinase tests performed on anti-CD158 and anti-CD16 immunoprecipitates, respectively, of NK RP cells
• TLE thin layer electrophoresis
• - Figure 4 shows a two-dimensional SDS-PAGE analysis under non-denaturing / denaturing conditions of anti-CD158 immunoprecipitates of NK RP cell lysates. having undergone a kinase test, and
• FIG. 5 shows the activating or non-inhibiting receptors of the immunoglobulin superfamily (IgSF) or of the lectin type, and their inhibiting counterparts,
• IgSF immunoglobulin superfamily
• FIG. 6 represents the schematic structure of KIR ( P 58) and KAR (p50) receptors
• FIG. 7 represents the cDNA sequence of a mouse KARAP polypeptide according to the invention (SEQ LD No. 1),
• FIG. 8 represents the nucleotide sequence (between the excluded leader sequence and the stop codon) and the amino acid sequence of a KARAP polypeptide according to the invention (mature protein, SEQ LD n ° 2), and
• FIG. 9 represents the alignment of the ITAMs and of the ITAM of a KARAP polypeptide according to the invention.
• FIGS. 10A, 11A, 12A, 13A and 14A respectively illustrate the cDNA sequences of ESTs AA242315, AA734769, W88159, AA098506 and W41142 (SEQ LD n ° 6 to SEQ LD n ° 10),
• FIGS. 10B, 11B, 12B, 13B and 14B respectively illustrate the protein sequences of ESTs AA242315, AA734769, W88159, AA098506 and W41142 (SEQ LD n ° 1 to SEQ LD n ° 15),
• FIG. 15 represents the alignment of the cDNA sequences of the ESTs AA242315, AA734769, W88159, AA098506 and W41142, and the resulting consensus sequence (SEQ ID No. 16; cDNA KARAP of mouse C57B1 / 6 consensus),
• FIG. 16 represents the alignment of the protein sequences of ESTs AA242315, AA734769, W88159, AA098506 and W41142, and the resulting consensus sequence (SEQ LD n ° 17; mouse KARAP protein C57B1 / 6 consensus),
• FIG. 17 represents the sequence of the KARAP gene from mouse line 129 (SEQ LD n ° 18; 2838 bp),
• FIG. 18 represents the genomic organization of the KARAP of line 129 mice
• - Figure 19 represents the cDNA sequence of the KARAP of line 129 mice (SEQ LD n ° 27) and the corresponding protein sequence (SEQ LD n ° 28 ),
• FIG. 20 represents from top to bottom, the genomic organization of the KARAP gene from mouse line 129, the corresponding protein sequence, and the nature of the different regions of this protein,
• FIG. 21 represents the cDNA of human KARAP (SEQ LD n ° 31),
• FIG. 22 shows the percentage of serotonin released into the supernatant by RBL-2H3 cells doubly transfected p50 / human KARAP, and stimulated by the antibody indicated on the abscissa (left: no antibody; in the mouse IgE center: mlgE 1 / 500; right: GL183 5 ⁇ g / ml),
• FIG. 23 illustrates the methodology between the organization of the human KAPAP gene and that of the murine KARAP gene.
• anti-CD3, anti-CD16 and anti-CD56 antibodies of isotype IgGl such as JT3A (Coulter Immunotech reference 0178), KDl (Coulter Immunotech reference 0813) and TA181.H12 (Coulter Immunotech reference 1844), respectively, - anti-CD3 ⁇ antico ⁇ s such as TIA-2 (Coulter Immunotech 66045P2),
• anti-CD158 antico ⁇ s namely anti-p58.1 antico ⁇ s such as EB6 (Coulter Immunotech reference 1847), anti-p58.2 antico ⁇ s such as GL183 (Coulter Immunotech reference 1846) and anti-p50.3 antico ⁇ s such as PAX250 described in Bottino et al. (Eur. J. Immunol. 1996, 26, 1816),
• an anti-Fc ⁇ RI ⁇ rabbit antiserum such as the antiserum 666 described in Jouvin M.H. et al., 1994, J. Biol. Chem. 269, 5918-5925,
• an anti-Fc ⁇ RI ⁇ rabbit antiserum such as the BC4 antiserum described in Bociano L.K. et al., 1986, J. Biol. Biochem. 261, 11823-1 1831,
• GL183-PE Coulter-Immunotech 2278
• EB6-Phycoerythrin EB6-PE
• a goat anti-mouse-phycoerythrin immunoglobulin anti-mouse-PE
• the lysis buffer contained 25 mM Tris-HCl pH 7.5; NaCl
• the Thin Film Electrophoresis Buffer contained 10% glacial acetic acid and 1% pyridine in water; pH 3.5. Cells
• Human NK cells from LDGL patients or LDGL cells Human NK cells from LDGL patients or LDGL cells:
• Human NK cells were obtained from patients with lymphoproliferative disease of granular lymphocytes (LDGL, Lymphoproliferative Disease of Granular Lymphocytes) of the NK cell line CD56 + , CD16 + , CD3 " .
• Peripheral blood lymphocytes PBL, Peripheral Blood Lymphocyte
• PBL Peripheral Blood Lymphocyte
• RPMI-1640 at 10 ⁇ g / ml of penicillin-streptomycin and 10% fetal calf serum, in the presence of irradiated allogeneic feeder cells and 100 U / ml of rLL-2.
• FIG. 6 schematically represents the structure of KIR p58 receptors (human inhibitors of the immunoglobulin type) and of KAR p50 receptors (non-inhibitory counterpart of the KIR p58 receptors).
• the RTILB cells used are the cells conventionally described as being RBL-2H3 cells transfected so as to express the murine Fc ⁇ RIIb2 receptor and the chimeric molecule CD25 / CD3 comprising the complete ecto- and trans-membrane domains of human CD25 linked to the complete intracytoplasmic domain of murine CD3.
• RTI B cells were further transfected by electroporation of 183.Act2 cDNA (coding for p50.283) carried on the expression vector RSV-5gpt.
• Stable RTILB.p50.2 + transfected cells were established by culture in the presence of xanthine (250 ⁇ g / 1), hypoxanthine (13.6 ⁇ g / 1) and mycophenolic acid (2 ⁇ g / 1).
• the cytolytic activity of the LDGL cells cultured on LL-2 was measured relative to the murine cell line P815 (American Type Culture Collection) in the absence or in the presence of the anti-CD16, anti-CD158 and anti-CD56 mAbs.
• the cells (10 - 50 x 10 6 ) were fixed with 0.5% formaldehyde in PB S (sodium phosphate buffer), then permeabilized for
• the cells were lysed for 30 minutes at 4 ° C in digitonin lysis buffer.
• the pre-purified post-nuclear supernatants were then immunoprecipitated using specific antibodies covering S4B-Sepharose beads (Pharmacia, Piscataway, NJ, USA) (Vivier E. et al., 1991, J. Immunol. 146 : 206).
• the immunoprecipitates were analyzed by SDS-PAGE (protein resolution by gel electrophoresis and sodium dodecylsulfate) and autoradiography.
• the cells (10 x 10 6 per sample) were lysed in 1 ml of lysis buffer (see reagents).
• the prepurified post-nuclear supernatants were immunoprecipitated for 2 to 3 hours using monoclonal antibodies linked covalently to a Sepharose 4B activated by CnBr (Pharmacia).
• the immune complexes were washed three times in lysis buffer; 40 ⁇ l of kinase buffer (see reagents) were then added to the immunoprecipitates for 10 minutes at 37 ° C.
• the kinase reaction was stopped by adding SDS-sample reducing buffer.
• the samples were brought to the boil before analysis by SDS-PAGE and autoradiography. In some experiments, the samples were analyzed by two-dimensional non-denaturing / denaturing diagonal SDS-PAGE.
• the phosphorylated proteins were excised from the dried gels and were eluted using a Centrilutor (Amicon) or a solution of SDS (sodium dodecyl sulfate) in 0.1%. PBS (sodium phosphate buffer). The Eluted proteins were precipitated in 20% trichloroacetic acid at 4 ° C for 2 hours, prior to incubation in 200 ⁇ l of 5.7 M HCl at 110 ° C. for 90 minutes.
• the immunoprecipitates were resolved by SDS-PAGE, transferred to nitrocellulose filters and compared with anti-CD3 ⁇ or anti-FC ⁇ RI ⁇ probes diluted in a solution of PB S at 5% in dehydrated skimmed milk.
• the immunotransferts were revealed using an anti-mouse or anti-rabbit goat antiserum conjugated with horseradish peroxidase (Sigma references A-2304 and A-0545 respectively) and the ECL detection system marketed by Amersham (RPN 2209).
• NK cells from LDGL patients and cultured on LL-2 interleukin-2
• FACScan sorting of fluorescently activated cells
• FIG. 1A an analysis by FACScan in indirect immunofluorescence of LDGL cells (lymphoproliferative disease of granular lymphocytes) RP, DF or MAL is presented. grown on LL-2.
• a goat anti-mouse immunoglobulin conjugated to fluorescein isothiocyanate served as the second step reagent.
• LDGL RP cells for the analyzes presented in the upper horizontal band
• LDGL DF cells for those in the middle horizontal band
• LDGL MAL cells for those in the lower horizontal band
• control treatment C for the graphs presented on the left or treatment with the indicated monoclonal antibody, either from left to right
• anti-CD3, anti-CD16, anti-CD158 EB6, anti-CD158 GL183, anti-CD158 PAX 250 are plotted, on the abscissa, the fluorescence intensities and, on the ordinate, the relative number of cells.
• - NK RP, DF and MAL cells are all CD3 " and CD16 + ,
• - NK R cells are p50.1 + , p50.2 “ , p50.3 “ : they are recognized by the anti-CD158 EB6 monoclonal antibodies and are not recognized by the anti-CDl 58 GL183 and PAX250 monoclonal antibodies,
• the NK DF cells are p50.1 " , p50.2 + , p50.3 " : they are recognized by the anti-CDl 58 GL183 monoclonal antibodies and are not recognized by the anti-CDl 58 EB6 and PAX250 monoclonal antibodies ,
• - NK MAL cells are p50.1 " , p50.2 ⁇ p50.3 + : they are recognized by the anti-CDl 58 PAX250 monoclonal antibodies and are not recognized by the anti-CDl 58 EB6 and GL183 monoclonal antibodies.
• NK cell lymphoproliferation recognized by anti-CDl 58 antibodies anti-KTR p58.1 (EB6), anti-KTR p58.2 (GL183) and anti-KAR p50.3 (PAX250) respectively.
• Three groups of NK cells were thus defined: LDGL RP cells, LDGL DF cells and LDGL MAL cells.
• NK cells from the donors indicated (RP. P50.1 + on the left, DF p50.2 + in the center, or MAL p50.3 + on the right) and cultured on LL-2 were used as effector cells.
• the test was carried out in the presence of: no antico ⁇ s (white circles), monoclonal anti-CDl 6 antico ⁇ s (black triangles), anti-CD56 monoclonal antico ⁇ s (white triangles), anti-CDl 58 monoclonal antico ⁇ s (EB6 for RP, GL183 for DF and PAX250 for MAL.) (Black circles).
• target cell ratios E: T ratio: 8: 1; 4: 1; 2: 1; 1: 1; 0.5: 1; 0.25: 1 and, on the ordinate, the percentage of specific lysis, (scale from 0 to 120%).
• the re-directed cytotoxicity tests indicate that, by contrast with what is observed during stimulation of KIR receptors, the addition of anti-CDl 58 antibodies to NK cells considerably increases the cytolysis of P815 cells ( Figure 1B) .
• the anti-CDl 6 monoclonal antibodies increase the spontaneous cytolysis of P815 in a similar way to the anti-CDl 58 monoclonal antibodies, while an anti-CD56 monoclonal antibody paired with the isotype has no effect (Figure 1B).
• NK cells therefore express on their surface KARs, the activating isoform of KIRs.
• LDGL LDGL were analyzed by internal radioiodination followed by immunoprecipitation. The results are illustrated in Figure 2A where an analysis is presented
• the immunoprecipitates of anti-CDl 58 antico ⁇ s prepared from lysates of NK cells contain, in addition to the KARs observed at ⁇ 50 kDa, a band of lower molecular mass migrating at 12
• KARAPs KAR-associated proteins, proteins associated with KARs
• FIG. 2B results, obtained in the presence of anti-CD3 ⁇ antico ⁇ s, are illustrated in FIG. 2B where an analysis of complete lysates of DF cells or of immunoprecipitates of such lysates is presented by SDS-PAGE resolution on 15% gel under denaturing conditions and incubation of the nitrocellulose filters with an anti-CD3 ⁇ monoclonal antico ⁇ s probe (marking arrow on the right).
• the complete cell lysates (LCC) DF were deposited at 5 x 10 6 cells / lane in track 1, the immunoprecipitates of such lysates at 15 x 10 6 cells / lane in tracks 2 to 4.
• the immunoprecipitations were carried out on DF cell lysates using the anti-Fc ⁇ RI ⁇ BC4 monoclonal antibody in control lane 2, the anti-CDl 6 monoclonal antibody in lane 3 and the anti-CDl 58 monoclonal antico 58s GL183 in lane 4.
• KARs are associated with predominantly low molecular weight phosphoprotein migrating at around 14 ⁇ 1 kDa in NK cells.
• FIG. 3A lysates prepared from NK MAL cells. were immunoprecipitated with the indicated antico ⁇ s (anti-Fc ⁇ RI ⁇ in track 1, anti-CD16 in track 2, anti-CD168 in track 3) prior to in vitro kinase tests.
• the phosphorylated proteins were separated by SDS-PAGE on a 15% gel under denaturing conditions.
• the immunoprecipitates of anti-CDl 58 mAbs prepared from NK KAR + cells comprise two other phospho- KARAPs, migrating at 16 ⁇ 1 kDa and 12 + 1 kDa respectively (indicated by an asterisk on either side of the KARAP deflection at 14 kDa in Figure 3A).
• the association of KARs with a similar group of phosphorylated KARAPs was also observed with a panel of clones of NK KAR + cells and was absent from NK KLR + clones.
• FIG. 3C The results are illustrated in FIG. 3C: the KARAPs (left) and CD3 ⁇ (right) bands were excised after kinase test in vitro and subjected to an analysis of the phophorylated amino acids by thin layer electrophoresis.
• the KARAPs and CD3 ⁇ bands were isolated from immunoprecipitates of monoclonal antico ⁇ s, respectively, anti-CDl 58 and anti-CD16 prepared from lysates of NK cells. RP.
• phosphorylation at the level of serine residues but not at the level of threonine residues can also be detected.
• the analysis of phophorylated amino acids confirmed the phosphorylation of CD3 ⁇ at the level of the tyrosine residue only.
• the in vitro kinase tests carried out on the immunoprecipitates of anti-CD1 58 monoclonal antico ⁇ s prepared from transfectants of RBL-2H3 p50.2 + cells did not include any detectable KARAP.
• FIG. 3B lysates prepared from RBL-2H3 p50.2 + cells were immunoprecipitated with the indicated antico ⁇ s (anti-CD3 ⁇ in track 1, anti-Fc ⁇ RI ⁇ in track 2, anti-CDl 58 lane 3) prior to in vitro kinase tests.
• the phosphorylated proteins were separated by SDS-PAGE on a 15% gel under denaturing conditions.
• KARAPs therefore associate selectively with KARs, and the absence of association of KARs with KARAPs is correlated with the inability of KARs to transduce any detectable activating signal.
• KARs autonomous activating receptors, in particular for MHC class I molecules, or co-receptors for TCR (T lymphocyte receptor) or RFc (receptor for constant fragment of immunoglobulin), represent a new pathway for activation.
• KARs are in fact assembled in NK cells into a multimeric complex involving associated KARAPs in the form of dimers linked by disulfide bond.
• the radioiodination analysis revealed a KARAP at approximately 12 ⁇ 1 kDa
• the kinase test analysis revealed three phospho-KARAPs at approximately 16, 14 and 12 ⁇ 1 kDa.
• the correlation between the association of KARs with KARAPs and the activating function of KARs suggests that KARAPs act as transducing subunits of the multimeric KAR complex.
• activating, or at least non-inhibiting, receptors for the immunoglobulin superfamily show striking similarities to p50 KARs (human immunoglobulin-type KARs): human KAR lectin-type NKG2C / D receptors, murine KAR receptors immunoglobulin pir A type, gp49A, murine KAR receptors of the lectin type Ly49D, Ly49H, but also human activating receptors of the LIR / MIR / LLT family such as LLT 1.
• FIG. 5 presents the activating or non-inhibiting receptors of the immunoglobulin superfamily (IgSF) or of the lectin type, and their inhibiting counterparts.
• IgSF immunoglobulin superfamily
• FIG. 5 presents the activating or non-inhibiting receptors of the immunoglobulin superfamily (IgSF) or of the lectin type, and their inhibiting counterparts.
• mPIR-B-mPIR-A, LLT2-LLT1, SIRP ⁇ -SIRP ⁇ , KTR-KAR, Fc ⁇ RITB- Fc ⁇ PJII, NKG2A / B-NKG2C / D, mLy49A / B / C / E / F / G / I-mLy49D / H) the cells expressing them naturally are indicated.
• TM transmembrane domain
• R arginine
• K lysine
• D aspartic acid
• E glutamic acid
• the inhibitory counterparts include an ITLM motif in their intracytoplasmic (IC) part.
• Each activating or non-inhibiting receptor exhibits, at the extracytoplasmic (EC) level, a strong homology with its inhibiting counterpart.
• EXAMPLE 2 The biochemical characterization of the KARAPs molecules (cf. example 1 above) has enabled us to specify the main identification criteria for the KARAP polypeptides, and in particular: - polypeptides comprising an amino acid cysteine extracytoplasmic, allowing the formation of disulfide bridges (cf. Figure 4)
• KARAPs a major characteristic of KARAPs lies in their selective association with KARs, and not with KIRs. Since, unlike KIRs, KARs have a transmembrane charged amino acid (lysine: K), and this characteristic is also at the basis of the association of polypeptides with ITAM present in the CD3 / TCR, BCR, Fc ⁇ RI complexes and Fc ⁇ RLLLA (CD 16), we oriented our strategy for identifying the KARAP gene by considering that KARAP is a new member of the family of ITAM transmembrane polypeptides. The latter indeed share with KARAP the same characteristics: -polypeptides comprising an amino acid cysteine extracytoplasmic
• FIG. 7 represents the DNA sequence (SEQ LD no. 1 cDNA) of a KARAP polypeptide according to the invention; this sequence corresponds to the sequence of the mouse KARAP gene.
• FIG. 8 where the part of the nucleotide sequence of the KARAP gene (SEQ LD No. 1) which is between the leader sequence (excluded) and the stop codon is represented, and where is also represented, in below this nucleotide sequence, the corresponding amino acid sequence (1 letter code) (SEQ LD No. 2, 3 letter code), that is to say the amino acid sequence of the mouse KARAP protein mature according to the invention (SEQ LD n ° 2).
• the extracytoplasmic part comprises at least one amino acid cysteine (in fact two, C8 and ClO), a transmembrane amino acid (D25), and an intracytoplasmic ITAM (Y65QELQGQRHEVY76SDL).
• FIG. 9 illustrates the comparisons that can be made by alignment of sequences between the polypeptides with ITAMs previously described and the polypeptides according to the invention having one (or) ITAM motifs, and indicates the resulting consensus ITAM sequence:
• FIG. 9 represents the alignment of the ITAMs of polypeptides with ITAM (six CD3, one Ig ⁇ , one Ig ⁇ , Fc ⁇ RI ⁇ and Fc ⁇ RI ⁇ ) and of an ITAM motif of the murine KARAP polypeptide (SEQ ID No. 2) identified above according to the invention (indicated "KARAP" in this FIG. 9) .
• KARAP is a new molecule transmembrane with ITAM which s associates with KAR and which, in a phosphorylated tyrosine form, associates with ZAP-70.
• KARAP is therefore a new transduction element for T and NK lymphocytes. It is possible that KARAP or analogs of KARAP also associate with the activating isoforms of the ITLM receptors, and serve in these multimolecular complexes as a subunit of transduction of the signals emitted during the engagement of the receptor.
• a particularly suitable method for determining or checking that a candidate polypeptide, the sequence of which is known, corresponds to a KARAP protein according to the invention consists in producing an antico ⁇ s against a characteristic part of this candidate polypeptide (for example a region intracytoplasmic comprising at least one ITAM motif or an extracytoplasmic region), and to verify that this antico ⁇ s recognizes, on a functional cell, a functional KAR + cell for example, a target which is associated with the receptor for which the candidate polypeptide is supposed to be KARAP (that is to say, in the case of KAR + cells, to verify that the antibody recognizes a target which is associated with a KAR receptor).
• a characteristic part of this candidate polypeptide for example a region intracytoplasmic comprising at least one ITAM motif or an extracytoplasmic region
• This method of identifying KARAP polypeptides according to the invention thus consists in particular in:
• the candidate polypeptide as being a KARAP polypeptide according to the invention when in the reaction products possibly formed there is a product of apparent molecular mass close to that of a KAR (approximately 50 kDa) and im product of close apparent molecular mass that of the candidate polypeptide in particular between 10 and 16 kDa approximately).
• This identification method according to the invention can in particular be carried out:
• KARAP KARAP. These are EST AA242315, AA734769, W88159, AA098506 and
• FIGS. 10A to 14A illustrate the cDNA sequences, respectively, of ESTs AA242315, AA734769, W88159, respectively, AA098506 and W41142 (SEQ ID No. 6 to SEQ ID No. 10 respectively).
• FIGS. 10B to 14B illustrate the protein sequences corresponding, respectively, to these ESTs (SEQ LD No. 11 to SEQ LD No. 15 for the proteins of ESTs AA242315, AA734769, W88159, AA098506 and W41142 respectively). All of these ESTs were obtained from tissues originating from C57B1 / 6 mice and were aligned in order to obtain a cDNA sequence corresponding to an open reading frame. This is illustrated by FIG. 15 which represents the alignment of the sequences of ESTs AA098506 (SEQ LD n ° 9),
• FIG. 16 represents the alignment of the protein sequences of ESTs AA242315 (SEQ LD n ° ll), W88159 (SEQ LD n ° 13), W41142 (SEQ LD n ° 15), AA098506 (SEQ LD n ° 14) and AA734769 (SEQ LD n ° 12), and which represents the resulting consensus sequence (murine consensus KARAP protein, SEQ LD n ° 17).
• the symbol ".” indicates an identity with the consensus sequence considered, the symbol "-" indicates the absence of sequencing data.
• a library (phage lambda, EMBL3) of genomic DNA isolated from mice of mouse line 129 was screened with cDNA corresponding to the sequence of EST AA734769 according to a conventional technique. A phage containing an 18 kb fragment was identified as positive. A mapping of this phage by cleavage with a series of restriction enzymes was carried out and a 9 kb EcoRI-EcoRI fragment obtained from the phage was cloned into the cloning vector pBlue-Script and contains the entire KARAP gene. murine (from the initial ATG to the STOP sequence). The sequence of this murine KARAP gene is presented in FIG. 17 (SEQ LD n ° 18; 2838 bp). In addition, oligonucleotide primers were generated in order to obtain the genomic organization of murine KARAP. The primers used are presented in table 1 below (SEQ LD n ° 19 to SEQ LD n ° 26): Board
• Exon 1 codes for an N-terminal portion of the signal sequence
• exon 2 codes for the rest of the signal sequence and the first three amino acids of the extracytoplasmic part
• exon 3 codes for the rest of the extracytoplasmic part
• exon 4 codes for 14 amino acids of the intracytoplasmic part
• exon 5 codes for the rest of the protein.
• ITAM polypeptide such as KARAP
• ITAM is encoded by two exons (exon 4 and 5) separated by a type 0 intron. 3 ° Functional reconstruction of a KAR (p50.2) expressed in the RBL-2H3 by the human KARAP DAP-12.
• RNA extracted from human NAR KAR + clones served as the basis for the generation of this cDNA.
• This cDNA was cloned into the eukaryotic expression vector pNT-neo and stable transfectants for this human KARAP were generated in the KAR + transfectant (p50.2) of the RBL-2H3 cell line (Bléry et al, J. Biol. Chem., 1997).
• the capacity of the KAR receptors expressed on the RBL-2H3 cells thus doubly transfected p50.2 + and KARAP + , to transduce an activating signal was tested by stimulation using antibodies directed against the extracytoplasmic part of p50.2 and following the release of tritiated serotonin.
• FIG. 23 illustrates the homology between the organization of the human KARAP gene and that of the murine KARAP gene (E1 to E5: exon 1 to exon 5; II to 14: intron 1 to intron 4). The numbering of the base pairs of the human and mouse KARAP gene is indicated there.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Cell Biology (AREA)
• Toxicology (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Animal Behavior & Ethology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=26233499

Family Applications (1)

Country Status (5)

Families Citing this family (7)

Family Cites Families (1)

• 1998
  • 1998-04-30 EP EP98921586A patent/EP0977855A2/fr not_active Withdrawn
  • 1998-04-30 JP JP54668798A patent/JP2002503094A/ja active Pending
  • 1998-04-30 CA CA002287916A patent/CA2287916A1/fr not_active Abandoned
  • 1998-04-30 WO PCT/FR1998/000883 patent/WO1998049292A2/fr active Application Filing
• 2004
  • 2004-08-02 US US10/902,886 patent/US7569666B2/en not_active Expired - Fee Related
• 2008
  • 2008-06-11 JP JP2008153485A patent/JP2009005699A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events